Economic evaluations of hepatitis B immunization: A global review of recent studies (1994-2000)

Health Economics

Volumn 10, Issue 8, 2001, Pages 751-774

  Beutels, Philippe ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cost effectiveness; Economic evaluation; Hepatitis B; Modelling; Vaccination

Indexed keywords

HEPATITIS B VACCINE;

ACCURACY; ACTIVE IMMUNIZATION; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; ENDEMIC DISEASE; FEMALE; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; INFANT; INFECTION PREVENTION; INFECTION RISK; INTERMETHOD COMPARISON; MALE; METHODOLOGY; NEWBORN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; VACCINATION;

COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; ENDEMIC DISEASES; HEALTH SERVICES RESEARCH; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; MODELS, ECONOMETRIC;

EID: 0035669801     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.625     Document Type: Article

References (74)

1. Status of hepatitis B immunization programmes in 1998
2. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
3. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study
4. Is vaccination against hepatitis B efficient? A review of world literature
5. Hepatitis B vaccine: A pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus
6. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies
7. Hepatitis B immunization strategies: Expanding the target
8. Substantial decline of notified hepatitis B in major parts of Europe after 1985
9. Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine
10. Universal hepatitis B vaccination in Flanders: Cost-effective?
11. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program
12. Analyse coût-avantage d'une politique de prévention vaccinale de l'hépatite virale B
13. Prevention of hepatitis B virus transmission by immunization
14. Economic evaluations applied to hepatitis B vaccination: General observations
15. Hepatitis B vaccination: The cost-effectiveness of alternative strategies in England and Wales
16. Gains in life expectancy from medical interventions-standardizing data on outcomes
17. Methodological quality of economic modelling studies: A case study with hepatitis B vaccines
18. The use of mathematical models in the epidemiological study of infectious diseases and in the design of mass immunization programmes
19. Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies
20. Evaluating the cost-effectiveness of vaccination programmes: A dynamic perspective
21. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state
22. Epidemiology of hepatitis B
23. The influence of age on the development of the hepatitis B carrier state
24. The transmission dynamics and control of hepatitis B virus in The Gambia
25. Vaccination against hepatitis B virus in highly endemic areas: Waning vaccine-induced immunity and the need for booster doses
26. Discounting costs and effects: A reconsideration
27. Discounting and health benefits
28. Discounting in health care decision-making: Time for a change?
29. For the panel on Cost-Effectiveness in Health and Medicine. Recommendations of the panel on Cost-Effectiveness in Health and Medicine
30. An economic evaluation of universal vaccination against hepatitis B virus
31. Economic foundations of cost-effectiveness analysis
32. Accounting for future costs in medical cost-effectiveness analysis
33. Theoretical issues in cost-effectiveness analysis
34. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
35. Targeted hepatitis B vaccination-a cost-effective immunisation strategy for the UK?
36. Ante-natal screening for hepatitis B surface antigen: An appraisal of its value in a low prevalence area
37. An appraisal of the efficacy and cost-effectiveness of antenatal screening for hepatitis B
38. Screening of pregnant women for hepatitis B and immunisation of babies at risk (HSC 1998/127)
39. Cost of acute hepatitis B infection in Swedish adults
40. Hepatitis B vaccination should be extended to include children
41. Acceptability of clinics for sexually transmitted diseases among users of the 'gay scene' in the West Midlands
42. The United Kingdom's hepatitis B immunisation strategy-where now?
43. Enhanced surveillance of acute symptomatic hepatitis B in England and Wales
44. Harm reduction measures and injecting inside prison versus mandatory drug testing: Results of a cross sectional anonymous questionnaire survey
45. Hepatitis B virus infection in patients attending a genitourinary medicine clinic: Risk factors and vaccine coverage
46. Is the strategy of universal hepatitis B vaccination necessary in low-endemic countries?
47. The prevalence of hepatitis B and hepatitis C in an antenatal population of various ethnic origins
48. Control of hepatitis B in the United Kingdom
49. Developed countries could pay for hepatitis B vaccination in developing countries
50. Why the Scandinavian countries have not implemented universal vaccination against hepatitis B
51. Are booster immunisations needed for lifelong hepatitis B immunity?
52. Economic evaluation of different vaccination strategies against hepatitis B in Switzerland
53. Hepatitis B immunization in a low-incidence province of Canada: Comparing alternative strategies
54. Economic evaluation of different vaccination strategies against hepatitis B for children and adolescents
55. Immunization programme against hepatitis B virus infection in Italy: Cost-effectiveness
56. Vaccination against hepatitis B virus in Spain: A cost-effectiveness analysis
57. Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain
58. Cost-effectiveness analysis of different universal vaccination strategies against hepatitis B in the region of Murcia
59. Differences in the methodology and data of economic evaluations of a health programme: The case of hepatitis B vaccination programmes in Spain
60. Hepatitis B immunization program: Spain
61. Cost-benefit analysis of hepatitis B immunisation for newborns in Romania
62. Is Romania's hepatitis B immunisation programme sustainable?
63. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity
64. Cost-effectiveness of hepatitis B vaccine in Greece
65. Cost-benefit analysis on immunisation of newborns with hepatitis B vaccine in Jinan City
66. Cost-effectiveness of hepatitis B vaccine in The Gambia
67. Calculating the global burden of disease: Time for a strategic reappraisal?
68. The cost-effectiveness of hepatitis B virus immunisation in The Gambia
69. Hepatitis B virus eradication strategy for Asia
70. Prevention and control of hepatitis B in central and eastern Europe and the Newly Independent States, Siofok, Hungary, 6-9 October 1996
71. Epidemiology of hepatitis B and C in Europe